Page 47 - 2021 Taiwan Food and Drug Administration Annual Report
P. 47
were submitted to international journals to IV. Continued to strengthen GMP
SURPRWH WKH UHVXOWV RI WKH FRXQWU\¶V H൵RUWV management through the PIC/
S platform
III. Reinforced bilateral medical
interaction between Taiwan By participating in PIC/S affairs and
and Japan DFWLYLWLHV 7)'$ FRXOG LQYROYH GLUHFWO\ LQWR
the revision of PIC/S guideline documents
The conference promoted the mutual ex- DQG $LGH 0HPRLUHV DQG LQFRUSRUDWLQJ QHZ
change and the understanding of regulations knowledge of remote GMP assessment of
as well as information between the two par- pharmaceutical manufacturers into current
ties. It hence strengthened trust and the col- UHJXODWLRQ DOVR JUHDWO\ LPSURYHG WKH LQ-
ODERUDWLRQ EHWZHHQ WKH JRYHUQPHQW R൶FLDOV VSHFWLRQ VNLOO RI LQVSHFWRUV %HVLGHV UHPRWH
DQG LQGXVWU\ SUDFWLWLRQHUV IURP WKH WZR VLGHV GMP assessment in response to restrictions
and also helped the practitioners to plan their on overseas traveling caused by the pan-
strategies in the international market which demic would ensure the GMP compliance of
would further promote the development of oversea pharmaceutical manufacturers.
domestic industry (Figure 3-2).
Figure3-2 8th Joint Conference of Taiwan and Japan on Medical Products Regulation
45
